Cannara Biotech (TSXV:LOVE) EV-to-EBIT : 11.92 (As of May. 24, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cannara Biotech's Enterprise Value is C$117.43 Mil. Cannara Biotech's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was C$9.85 Mil. Therefore, Cannara Biotech's EV-to-EBIT for today is 11.92.

The historical rank and industry rank for Cannara Biotech's EV-to-EBIT or its related term are showing as below:

TSXV:LOVE' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.39 Med: 10.39 Max: 4113.24
Current: 11.92

During the past 6 years, the highest EV-to-EBIT of Cannara Biotech was 4113.24. The lowest was -27.39. And the median was 10.39.

TSXV:LOVE's EV-to-EBIT is ranked better than
64.93% of 670 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs TSXV:LOVE: 11.92

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cannara Biotech's Enterprise Value for the quarter that ended in Feb. 2024 was C$134.54 Mil. Cannara Biotech's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was C$9.85 Mil. Cannara Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was 7.32%.

Cannara Biotech EV-to-EBIT Historical Data

The historical data trend for Cannara Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech EV-to-EBIT Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

EV-to-EBIT

Get a 7-Day Free Trial

-8.64

-6.39

4,256.31

34.55

12.17

Cannara Biotech Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBIT	Get a 7-Day Free Trial															18.44	17.07	12.17	9.46	13.66

Competitive Comparison of Cannara Biotech's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's EV-to-EBIT falls into.

Cannara Biotech EV-to-EBIT Calculation

Cannara Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	117.434	/	9.852
	=	11.92

Cannara Biotech's current Enterprise Value is C$117.43 Mil.
Cannara Biotech's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$9.85 Mil.

Cannara Biotech (TSXV:LOVE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cannara Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2024 )	=	EBIT	/	Enterprise Value (Q: Feb. 2024 )
	=	9.852	/	134.53662
	=	7.32 %

Cannara Biotech's Enterprise Value for the quarter that ended in Feb. 2024 was C$134.54 Mil.
Cannara Biotech's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$9.85 Mil.

Cannara Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech (TSXV:LOVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

LOVFF:USA 8CB0:Germany

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Executives